Premium
New formulation with potential for the prevention and treatment of Osteoporosis and Osteoarthritis
Author(s) -
Torrent Anna,
Montell E.,
Vergés J.,
Ruhí R.,
Dalmau P.,
Carceller M.C.,
Blanco A.,
Terencio M.C.,
Ferrándiz M.L.,
Alcaraz M.J.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1053.6
Subject(s) - osteoarthritis , medicine , osteoporosis , cartilage , anterior cruciate ligament , vitamin d and neurology , urology , endocrinology , surgery , pathology , anatomy , alternative medicine
Objective The aim of this study was to investigate the effect of a new formulation in a combined rat model of Osteoporosis (OP) and Osteoarthritis (OA). The nutraceutical formulation (BIS073) contains mainly mucopolysaccharides, a source of calcium and Vitamin D3. Methods OP was induced by ovariectomy in female Wistar rats (n=15 rats/group) and 2 weeks after OA was induced by Anterior Cruciate Ligament Transection (ACLT). BIS073 was administered daily (oral gavage) at two doses (93.3 mg/kg/day and 280 mg/kg/day) from week 0 until week 12 after ovariectomy. A Control Group and Vehicle Group were also included. After week 12, animals were sacrificed. For the assessment of OA, histology was performed and cartilage degeneration was evaluated by means of the OARSI score. Bone microarchitecture and density were assessed by microCT. Results BIS073 has been shown to induce a statistically significant reduction (approximately 40%) of the cartilage degradation according to the OARSI score. MicroCT revealed that this treatment exerted a positive effect in bone structure, especially at the high dose. In addition, a significant reduction in the pro‐inflammatory cytokines IL‐1β and IL‐17 was observed. Conclusion Our data demonstrate that treatment with BIS073 could be an effective strategy to control the progression of experimental Osteoarthritis and Osteoporosis. Supported by BIOIBERICA S.A, Barcelona, Spain.